NOP receptor agonist (peptide)

NOP receptor agonist (peptide) is an oral, peripherally restricted peptide investigational medicine being developed by Grünenthal for the treatment of chronic peripheral neuropathic pain, including painful diabetic peripheral neuropathy. The drug selectively targets the nociceptin/orphanin FQ (NOP) receptor, a G protein-coupled receptor that plays a key role in pain modulation but is distinct from classical opioid receptors (mu, delta, and kappa). By restricting the drug's activity to the peripheral nervous system, Grünenthal aims to provide strong analgesic efficacy without the central nervous system-mediated side effects common to opioids, such as sedation, respiratory depression, and potential for misuse. The compound, likely identified as GRT6010 in clinical registries, is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics.

Other names

Nociceptin/Orphanin FQ receptor agonistperipherally restricted NOP receptor agonist